Nucleic acid-controlled catalytic rnas for trigger-responsive regulation
US-2024425855-A1 · Dec 26, 2024 · US
Methods for the treatment of Leber congenital amaurosis
US9012425B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9012425-B2 |
| Application number | US-201214125063-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 8, 2012 |
| Priority date | Jun 10, 2011 |
| Publication date | Apr 21, 2015 |
| Grant date | Apr 21, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a method for treating a Leber congenital amaurosis in a patient harboring the mutation c.2991+1655 A>G in the CEP290 gene, comprising the step of administering to said patient at least one antisense oligonucleotide complementary to nucleic acid sequence that is necessary for preventing splicing of the cryptic exon inserted into the mutant c.2291+1655 A>G CEP290 mRNA.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating a Leber congenital amaurosis in a patient harbouring the mutation c.2991+1655 A>G in the CEP290 gene comprising administering to the patient an effective amount of an antisense oligonucleotide which is SEQ ID NO:2 (ESE(+50+70)).
Assignees
- Rozet Jean-Michel
- Kichler Antoine
- Perrault Isabelle
- Kaplan Josseline
- Gerard Xavier
- Scherman Daniel
- Munnich M Arnold
- Inst Nat Sante Rech Med
- Centre Nat Rech Scient
- Genethon
- Univ Paris Descartes
- Enscp—Chimie Paris Tech—Ecole Nat Superieure De Chimie De Paris
- Univ D Evry Val D Essonne
- Assistance Publique—Hopitaux de Paris
Inventors
Classifications
Human Necessities · mapped topic
- C12N15/113Primary
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9012425B2 cover?
- The present invention relates to a method for treating a Leber congenital amaurosis in a patient harboring the mutation c.2991+1655 A>G in the CEP290 gene, comprising the step of administering to said patient at least one antisense oligonucleotide complementary to nucleic acid sequence that is necessary for preventing splicing of the cryptic exon inserted into the mutant c.2291+1655 A>G CEP290 …
- Who is the assignee on this patent?
- Rozet Jean-Michel, Kichler Antoine, Perrault Isabelle, and 11 more
- What technology area does this patent fall under?
- Primary CPC classification C12N15/113. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 21 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).